Abstracts tagged "Adverse events"

Abstract Number: 2167 • 2015 ACR/ARHP Annual Meeting
Application of Combined Reporting of Benefit and Harm (OMERACT 3×3 methodology) to the Rheumatoid Arthritis Comparison of Active Therapies Trial
Maarten Boers^1,2, Sarah Leatherman³, James R. O'Dell⁴ and Jeffrey R. Curtis⁵, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, ³MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Birmingham VAMC, Birmingham, AL
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Initiative has suggested an analysis of the occurrence of benefit and harm in trials simultaneously, at the individual…
Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Cheryl Barnabe¹, Yufei Zheng², Arto Ohinmaa², Brenda Hemmelgarn³, Gilaad Kaplan⁴, Liam Martin⁵ and Walter Maksymowych⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health Economics, Edmonton, AB, Canada, ³Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Medicine, Medicine, University of Alberta, Edmonton, AB, Canada
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…
Abstract Number: 552 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab
Gerd Burmester¹, Gurjit S. Kaeley², Arthur Kavanaugh³, Cem Gabay⁴, Daryl MacCarter⁵, Peter Nash⁶, Tsutomu Takeuchi⁷, Anabela Cardoso⁸, Shufang Liu⁹, Hartmut Kupper¹⁰ and Jasmina Kalabic¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of Florida, Jacksonville, FL, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁶Department of Medicine, University of Queensland, Brisbane, Australia, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸Torre Oriente, AbbVie, Lisboa, Portugal, ⁹Immunology Development, AbbVie, North Chicago, IL, ¹⁰AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Combination treatment of rheumatoid arthritis (RA) with methotrexate (MTX)+adalimumab (ADA) has been shown to be more effective than ADA monotherapy. However, MTX is associated…
Abstract Number: 561 • 2015 ACR/ARHP Annual Meeting
Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Jeffrey R. Curtis¹, Marc de Longueville², Cathy O'Brien² and Boulos Haraoui³, ¹University of Alabama at Birmingham, Birmingham, AL, ²UCB Pharma, Brussels, Belgium, ³Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Anti-TNF drugs are an effective treatment option for rheumatoid arthritis (RA) patients (pts) but have been associated with an increased incidence of serious infectious…
Abstract Number: 573 • 2015 ACR/ARHP Annual Meeting
Association Between Three Measures of Oral Glucocorticoid Exposure and Potential Adverse Events Among Patients with Rheumatoid Arthritis
Jennie Best¹, Amanda Farr², Gregory Lenhart², Khaled Sarsour¹, Marni Stott-Miller² and Yong Gil Hwang³, ¹Genentech, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Oral glucocorticoids are commonly used to treat rheumatoid arthritis (RA). However, their use may be associated with potential adverse events. Therefore, the objective was…
Abstract Number: 587 • 2015 ACR/ARHP Annual Meeting
Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio
Cindy Strehl¹, Johannes W J Bijlsma², Maarten de Wit³, Maurizio Cutolo⁴, Raphaele Seror⁵, Kevin L. Winthrop⁶, Frank Buttgereit¹ and EULAR Task Force on Glucocorticoids, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁵Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, ⁶Division of Infectious Diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Glucocorticoids (GC) are used to treat a wide range of inflammatory diseases including rheumatic and musculoskeletal diseases. EULAR recommendations on GC therapy are up…
Abstract Number: 619 • 2015 ACR/ARHP Annual Meeting
Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
Maria de Hair, Nicole IJff, Johannes Jacobs and Jacob van Laar, Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
On behalf of the Society for Rheumatology Research Utrecht (SRU) Background/Purpose: To investigate the frequency of long-term adverse events (AEs) in early rheumatoid arthritis (RA)…
Abstract Number: 884 • 2015 ACR/ARHP Annual Meeting
Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Nataliya Milman⁸, Jacqueline Peck⁹, Judy A. Shea¹⁰, Peter F. Cronholm⁴ and Peter A. Merkel¹¹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²NONE, Branbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹NONE, Oxford, United Kingdom, ¹⁰Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) comprise a group of multisystem diseases of the small blood vessels…
Abstract Number: 956 • 2015 ACR/ARHP Annual Meeting
The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events
Joost Swart¹, Angela Pistorio², Francesca Bovis³, Ekaterina Alexeeva⁴, Michael Hofer⁵, Susan Nielsen⁶, Jordi Anton⁷, Alessandro Consolaro⁸, Violeta Vladislava Panaviene⁹, Valda Stanevicha¹⁰, Maria Trachana¹¹, Constantin Ailioaie¹², Florence Uettwiller¹³, Fabrizio De Benedetti¹⁴, Elena Tsitsami¹⁵, Berit Flato¹⁶, Pavla Dolezalová¹⁷, Tamás Constantin¹⁸, Troels Herlin¹⁹, Sylvia Kamphuis²⁰, Sujata Sawhney²¹, Despoina Maritsi²², Veronika Vargova²³, Luca Villa⁸, Chiara Pallotti⁸, Angelo Ravelli³, Alberto Martini²⁴, Nico Wulffraat²⁵, Nicolino Ruperto²⁶ and on behalf of for PRINTO, ¹Pediatric Rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Servizio di Epidemiologia e Biostatistica, Istituto Giannina Gaslini, Genoa, Italy, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ⁵Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁶Pediatric Rheumatology Unit, Juliane Marie Centret, Rigshospitalet, Copenhagen, Denmark, ⁷Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ⁸Pediatria II - Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁹Centre of Pediatrics, Vilnius University, Vilnius, Lithuania, ¹⁰Department of Paediatrics, Riga Stradins University, Riga, Latvia, ¹¹1st Department of Pediatrics, Aristotle University, Thessaloniki, Greece, ¹²II Pediatric Clinic, Private Medical Clinic, IASI, Romania, ¹³Unité d'Immunologie, Hématologie et Rhumatologie Pediatrique, Université Paris-Descartes, IMAGINE Institute, Hôpital Necker-Enfants Malades, Paris, France, ¹⁴Reumatologia, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ¹⁵First Department of Pediatrics, Children Hospital Aghia Sophia, Athens, Greece, ¹⁶Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁷Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ¹⁸Unit of Paediatric Rheumatology, 2nd Dpt of Pediatrics, Semmelweis University, Budapest, Hungary, ¹⁹Department of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark, ²⁰Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²¹Paediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, ²²2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ²³1st Department of Paediatrics and Adolescent Medicine, Šafarik University and Children Faculty Hospital in Košice, Kosice, Slovakia, ²⁴Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy, ²⁵Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²⁶Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA) has greatly changed in the past 15 years thanks to the introduction of biologic agents but little is…
Abstract Number: 1403 • 2015 ACR/ARHP Annual Meeting
Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review of Case Reports
Noha Abdel-Wahab^1,2 and Maria E. Suarez-Almazor³, ¹Rheumatology & Rehabilitation Department, Assiut University Hospital, Egypt, Assiut, Egypt, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, USA, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Background: The recent discovery of the immune checkpoint blockade that targets the regulatory pathways in T cells to enhance antitumor immune responses has led…
Abstract Number: 462 • 2014 ACR/ARHP Annual Meeting
Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies
Bei-Hung Chang^1,2, Lien Quach¹, Mary Brophy³, Keri Hannagan⁴, Edward C. Keystone⁵, Ted R. Mikuls⁶ and James R. O'Dell⁷, ¹VA Boston Healthcare System, Boston, MA, ²Qualitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ³VA Boston Heathcare System, Boston, MA, ⁴MAVERIC, VA Boston Heathcare System, Boston, MA, ⁵Medicine, University of Toronto, Toronto, ON, Canada, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose TNF inhibitors and combinations of conventional disease-modifying antirheumatic drugs are commonly added to treat methotrexate non-responsive rheumatoid arthritis patients. In the 48-week double blind,…
Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting
Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Christos E. Lampropoulos¹, Philippos Orfanos², Vasiliki-Kalliopi Bournia³, Theofilos P. Karatsourakis⁴, Clio P. Mavragani⁵, Dimitrios Pikazis⁴, Menelaos N. Manoussakis⁶, Athanasios G. Tzioufas⁴, Haralampos M. Moutsopoulos⁷ and Panayiotis G. Vlachoyiannopoulos³, ¹Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ²Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, ³First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁵Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁷Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
Abstract Number: 477 • 2014 ACR/ARHP Annual Meeting
Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials
Richard Conway¹, Candice Low², Robert J. Coughlan¹, Martin O'Donnell³ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Medicine, St. James Hospital, Dublin, Ireland, ³Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose Leflunomide is an effective treatment for rheumatoid arthritis. An association between pulmonary adverse events, in particular interstitial lung disease, and leflunomide use has been…
Abstract Number: 471 • 2014 ACR/ARHP Annual Meeting
Improving of Safety in Treatment with Biologics during First Seven-Years Experiences; Long-Term Results from Observational Cohort Study of Clinical Practice Using Multicenter Registry in Japan
Toshihisa Kojima¹, Nobunori Takahashi¹, Koji Funahashi², Shuji Asai², Yutaka Yoshioka², Kenya Terabe², Nobuyuki Asai^2,3, Toki Takemoto², Naoki Ishiguro¹, Atsushi Kaneko⁴, Yuji Hirano⁵, Yuichiro Yabe⁶ and Yasuhide Kanayama⁷, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Nagoya Univeristy Hospital, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁵Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁶Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan, ⁷Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan
Background/Purpose: Many evidences including clinical trials of biologics lead us earlier and more aggressive treatment strategy for patients with rheumatoid arthritis (RA). It is stated…
Abstract Number: 468 • 2014 ACR/ARHP Annual Meeting
Identification of Baseline Risk Factors for Adverse Events in Certolizumab Pegol Treated Rheumatoid Arthritis Patients
Boulos Haraoui¹, John Wade², Marc de Longueville³, Pauline Ralston⁴ and Jeffrey R. Curtis⁵, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of British Columbia, and Vancouver General Hospital, Vancouver, BC, Canada, ³SA Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁴Giant Professional Ltd, London, United Kingdom, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Despite efficacy of anti-tumor necrosis factors (anti-TNFs) in treating chronic immune conditions, some patients (pts) report serious adverse events (SAEs) highlighting a need to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].